WallStreetZenWallStreetZen

NYSEMKT: CVM
Cel Sci Corp Stock

$2.24+0.16 (+7.69%)
Updated Mar 1, 2024
CVM Price
$2.24
Fair Value Price
N/A
Market Cap
$112.23M
52 Week Low
$1.04
52 Week High
$3.33
P/E
-3.25x
P/B
8.87x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$31.05M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.27
Operating Cash Flow
-$23M
Beta
0.94
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CVM Overview

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CVM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CVM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CVM is poor value based on its book value relative to its share price (8.87x), compared to the US Biotechnology industry average (6.18x)
P/B vs Industry Valuation
CVM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CVM due diligence checks available for Premium users.

Be the first to know about important CVM news, forecast changes, insider trades & much more!

Valuation

CVM price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.25x
Industry
15.19x
Market
36.17x

CVM price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
8.87x
Industry
6.18x
CVM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CVM's financial health

Profit margin

Revenue
$0.0
Net Income
-$6.7M
Profit Margin
0%
CVM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$28.7M
Liabilities
$16.1M
Debt to equity
1.27
CVM's short-term assets ($6.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CVM's long-term liabilities ($11.19M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CVM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CVM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.9M
Investing
-$64.9k
Financing
$4.0M
CVM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CVM vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CVM$112.23M+7.69%-3.25x8.87x
LIFE$111.85M-0.52%-1.97x1.14x
CYT$111.59M-0.32%-3.30x0.89x
ANIX$111.27M+0.29%-10.97x4.57x
BRNS$113.77M+4.24%-1.45x0.58x

Cel Sci Stock FAQ

What is Cel Sci's quote symbol?

(NYSEMKT: CVM) Cel Sci trades on the NYSEMKT under the ticker symbol CVM. Cel Sci stock quotes can also be displayed as NYSEMKT: CVM.

If you're new to stock investing, here's how to buy Cel Sci stock.

What is the 52 week high and low for Cel Sci (NYSEMKT: CVM)?

(NYSEMKT: CVM) Cel Sci's 52-week high was $3.33, and its 52-week low was $1.04. It is currently -32.73% from its 52-week high and 115.38% from its 52-week low.

How much is Cel Sci stock worth today?

(NYSEMKT: CVM) Cel Sci currently has 50,104,231 outstanding shares. With Cel Sci stock trading at $2.24 per share, the total value of Cel Sci stock (market capitalization) is $112.23M.

Cel Sci stock was originally listed at a price of $1,655.00 in Dec 31, 1997. If you had invested in Cel Sci stock at $1,655.00, your return over the last 26 years would have been -99.86%, for an annualized return of -22.43% (not including any dividends or dividend reinvestments).

How much is Cel Sci's stock price per share?

(NYSEMKT: CVM) Cel Sci stock price per share is $2.24 today (as of Mar 1, 2024).

What is Cel Sci's Market Cap?

(NYSEMKT: CVM) Cel Sci's market cap is $112.23M, as of Mar 3, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cel Sci's market cap is calculated by multiplying CVM's current stock price of $2.24 by CVM's total outstanding shares of 50,104,231.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.